Sideguard coronary stent success in Coronary Bifurcation Disease

Cappella Medical Devices Ltd a company developing solutions for the treatment of Coronary Bifurcation Disease, has announced the multicenter long term follow up results for its innovative Sideguard coronary sidebranch stent . Long term follow up data on the Sideguard stent was obtained from 399 patients from the United Kingdom, Germany, and Italy. The MACE rate was: 3.7% (30 day F/U), 7.1% (6 mo F/U) and 10.2% (1 year F/U) comparing favourably with existing standard practice.

This data represents the largest multicenter clinical experience to date with the Sideguard technology. Results from this multicenter experience have confirmed that preservation of the sidebranch of diseased coronary arteries by protecting the ostium has clear long term benefits when compared to existing standard practice of provisional and two-stent procedures.